Mastermind Genomic Search Engine to Provide Direct Links to Genomic Evidence Within SOPHiA’s Solutions.
HOUSTON (PRWEB) OCTOBER 15, 2019
Genomenon® announced today at the American Society of Human Genetics Annual Meeting (ASHG) a partnership with SOPHiA GENETICS that includes incorporating the Mastermind® Genomic Search Engine into the SOPHiA Platform and the Alamut Suite. The partnership puts the most up-to-date genomic research at the fingertips of clinical researchers performing genomic analysis worldwide.
The SOPHiA Platform is the technology of choice for streamlined Data-Driven Medicine, including clinical-grade genomic analysis, interpretation, and reporting. SOPHiA has been adopted by 1,000 healthcare institutions to date, and analyzed more than 420,000 genomic profiles – 16,000 new profiles processed each month. The Alamut Suite powered by SOPHiA is a decision-support software designed to explore and investigate variations of the human genome. Alamut helps clinical researchers in the complex tasks of genomic variants annotations, filtration and exploration.
With the addition of Mastermind, users of both technologies will be able to quickly access the genomic evidence associated with human variants, shortening the search time required to interpret a variant and assess its pathogenicity.
This partnership will allow SOPHiA’s users to see a wider picture of the detected variants. A key driver in the decision is the breadth and depth of Mastermind’s coverage of genomic variants and published literature. Mastermind has indexed over 7 million full text articles and 600,000 supplemental data sets and covers over 5.7 million variants found in the medical literature.
“This partnership will help experts better and more quickly assess the impact of accurately detected genomic variants in a clinical context. We are thrilled to be able to provide our users with all the necessary information they need to make the best possible decision for each case,” said Gioia Althoff, Senior Vice President, Genomics for SOPHiA.
“We’re excited to partner with SOPHiA to put the most comprehensive and up-to-date genomic research in the hands of geneticists and researchers performing genomic analysis.” said Mike Klein, CEO of Genomenon. “The broader adoption of Genomenon’s Mastermind provides significant value to our quickly growing customer base around the world.”
Genomenon connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases. Our flagship product, the Mastermind Genomic Search Engineis used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield and assure repeatability in reporting genetic testing results. We license our Mastermind Curated Genomic Datasets to pharmaceutical and bio-pharma companies to inform precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.
For more information, visit http://www.genomenon.com.
About SOPHiA Genetics
A leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech company that developed SOPHiA, an advanced AI technology helping healthcare professionals make sense of the large amount of clinical data. SOPHiA GENETICS is democratizing Data-Driven Medicine by enabling the rapid adoption of genomic and radiomic analysis worldwide, turning data into actionable insights, and sharing knowledge through its community of over 990 healthcare institutions in 82 countries in a sustainable and inclusive way. The company’s achievements and innovative approach is recognized by the MIT Technology Review “50 Smartest Companies”.
For more information, visit http://www.sophiagenetics.com
“(Mastermind) will help experts better and more quickly assess the impact of accurately detected genomic variants in a clinical context.”